The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Midas Minerals (ASX:MM1) has announced its geotech’s team identification of 17 spodumene pegmatite targets at its Canada Aylmer acreage.

The company reported assays of up to 7.76% lithium in rockchips with potential further instances yet to be found given some cover.

Assays are pending for a separate pegmatite from Argus.

The company is ultimately refining these targets to drill “at a later date”; the company noted it had a drill permit for five years at the project.

The explorer may just be waiting for a recovery in lithium prices.

“Field observations, including the abundance of spodumene-bearing pegmatite outcrops and occurrences of visible coarse spodumene at Aylmer are highly encouraging,” Midas chief Mark Calderwood said.

“Midas maintains a limited lithium exploration program, focussing on low-cost mapping and sampling with drilling deferred for the time being. The Company will however focus exploration on gold and copper targets on the Newington and Challa projects, in addition to ongoing project generation activities.”

MM1 last traded at 8.6cps.

MM1 by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…